IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients. - Wikidata - wikimedia - TriplyDB

IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.

IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.

http://www.wikidata.org/entity/Q37040481

about

Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.Serum cytokine profile of laryngeal squamous cell carcinoma patients.Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen.IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.

P2860

Q27307719-768BA484-648D-4B03-8350-DC5DBE858FB8 Q28071998-658D9900-B0F3-41FE-9FFE-266421691EA0 Q35940189-8FE55F6F-686D-4C66-9403-268EE98F453B Q37692604-8E7F15B4-163D-483C-A1F6-B4013E650CAE Q51063063-B84CC4EB-4D92-453D-A8CB-5FE891A43646 Q51098902-E4FCAAC3-A057-4DDE-B4AC-D80AA5903B78 Q55293126-B0B4AAFD-D8F3-482C-B02B-8B0BEFE37FF2 Q55515909-271E46B2-8684-455C-9964-90F6CD7F0BE1

P2860

IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.

http://www.wikidata.org/entity/Q37040481

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 January 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

IRX-2, a novel immunotherapeut ...... functions in cancer patients.

@en

IRX-2, a novel immunotherapeut ...... functions in cancer patients.

@nl

type

label

IRX-2, a novel immunotherapeut ...... functions in cancer patients.

@en

IRX-2, a novel immunotherapeut ...... functions in cancer patients.

@nl

prefLabel

IRX-2, a novel immunotherapeut ...... functions in cancer patients.

@en

IRX-2, a novel immunotherapeut ...... functions in cancer patients.

@nl

P1433

Q37040481-74109C0D-3CDC-4CFF-B849-BBC9A1CF482B

P1476

Q37040481-54CC0DAD-F21D-45A2-834D-B1E262EE4802

P2093

Q37040481-15BA5108-74AD-4F40-A3BB-CE8E411661B2

Q37040481-455CAAEE-3BDB-41BF-8545-E623626EBCFE

Q37040481-4591C5D2-D6FB-468B-A3BE-43B7471A556F

Q37040481-810A41F4-E0B0-4F16-9691-51350ACA66F7

Q37040481-AEFC13DD-A96A-4FCE-9169-215FFB11111C

Q37040481-CF45B465-2BD1-4615-929B-A335C27D8100

P2860

Q37040481-151C849E-5363-4131-9F50-3FC5D3818DA3

Q37040481-221365F4-1416-49E4-8CE3-6B165B31730E

Q37040481-2549ED62-DD29-4F82-BFEF-531618939C45

Q37040481-2F6A3558-EC6B-43DF-AB99-268F7EDF521C

Q37040481-397900C3-7BBE-4E24-9B1A-9EA92D13E84C

Q37040481-3E2446A6-5094-4B11-8E35-0CBB0DE8F1C4

Q37040481-3EC88118-561C-4933-88EC-AC89FC6C88D6

Q37040481-417F4B40-C397-40E9-B8A0-82470B9BE979

Q37040481-42C37E8A-A2DE-4C50-BE4A-EFDE4F023480

Q37040481-529C02D3-B7F0-4145-9FF4-4DCC0B57078B

P2888

Q37040481-7070022F-0D8C-4321-BE37-AA4CE3B100BA

P304

Q37040481-83246D48-4071-4D73-B462-E50C35ECE528

P31

Q37040481-7B69B83B-5242-442D-A503-290F97B752E5

P356

Q37040481-6D0BE433-FB58-41A0-A52C-D992A01212FE

P433

Q37040481-FCA4FB07-67C5-4971-89B8-66DC74A63F5E

P478

Q37040481-C1AC7793-C759-49E6-B323-23223757ADD7

P577

Q37040481-572E6C78-1984-4B96-91BC-41D5BE1FD718

P698

Q37040481-05309A84-8EFD-4D32-A787-73C0C56E6055

P921

Q37040481-5BF97CE6-62D2-4C5F-A6E0-C08649EB7205

P932

Q37040481-57299626-2F15-48A3-B60E-477B590DD0AE

P356

S00262-011-1197-X

P1433

Cancer Immunology, Immunotherapy

P1476

IRX-2, a novel immunotherapeut ...... functions in cancer patients.

@en

P2093

B Schilling

http://www.w3.org/2001/XMLSchema#string

E S Halstead

http://www.w3.org/2001/XMLSchema#string

J E Egan

http://www.w3.org/2001/XMLSchema#string

M Harasymczuk

http://www.w3.org/2001/XMLSchema#string

P Schuler

http://www.w3.org/2001/XMLSchema#string

T L Whiteside

http://www.w3.org/2001/XMLSchema#string

P2860

p46, a novel natural killer cell-specific surface molecule that mediates cell activation

Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells

Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

Innate or adaptive immunity? The example of natural killer cells

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.

Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.

TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells

Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1.

P2888

s00262-011-1197-x

P304

1395-1405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-011-1197-X

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22270713

http://www.w3.org/2001/XMLSchema#string

P921

P932

3721346

http://www.w3.org/2001/XMLSchema#string